ClinicalTrials.gg
CompletedNCT01361399Updated Oct 18, 2023

Active and Placebo Controlled Study to Test the Efficacy and Safety of an Aspirin-Lidocaine Lozenge in the Symptomatic Treatment of Sore Throat Associated With a Common Cold

A Phase 3 interventional study of Acetylsalicylic acid (Aspirin, BAYE4465) & Lidocain and Acetylsalicylic Acid (Aspirin, BAYE4465) in Common Cold, Pharyngitis and Tonsillitis, sponsored by Bayer. Completed at 19 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-18.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 6 years 5 months after the study started (first participant enrolled Nov 2004, registered May 2011).
Phase
Phase 3
Study type
Interventional
Enrollment
1,088
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to investigate the analgesic efficacy of a single dose of a fixed combination of 500 mg Aspirin (Acetylsalicylic Acid) and 4 mg Lidocaine in adult patients with sore throat associated with a common cold in comparison to a single treatment with 500 mg Aspirin or 4 mg Lidocaine alone as well a Placebo (treatment without any active ingredient). The combination of Aspirin and Lidocaine in a single lozenge is expected to provide relief from sore throat pain by sequential action. A very fast inset of action will be achieved by the locally acting Lidocaine and a long duration of action will be achieved by the systemically acting Aspirin.

02

Conditions studied

  • Common Cold
  • Pharyngitis
  • Tonsillitis

Keywords

  • Sore Throat
03

In context

Common Cold

219 studies on the registry are indexed under Common Cold; 23 are open to participants now.

This study's enrollment of 1,088 is above the median of 150 across 184 interventional studies indexed under Common Cold.

Browse Common Cold studies →

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females of at least 18 years of age
  • Onset of common cold within the last 3 days (12 to 72 hours)
  • History of at least 4 symptoms associated with URTI in the last 24 hours out of runny nose, stuffy nose, sneezing, wet cough, dry cough, sweating, earache, ear fullness, sinus pressure/pain, head heaviness, muscle aches and pains, feverish discomfort, chills, hoarseness, sore throat, scratchy throat and headache as documented in the history of URTI
  • Current sore throat confirmed by a score ≥ 6 on a 11-category vertical ordinal scale for sore throat pain
  • Findings that confirmed the presence of tonsillopharyngitis

Exclusion criteria

Exclusion Criteria:

  • Pregnancy (i.e. positive pregnancy test at baseline)
  • Breastfeeding
  • History of (allergic reaction) to ASA or any other NSAID
  • History of hypersensitivity (allergic reaction) to lidocaine
  • History or acute state of peptic ulceration or gastrointestinal bleeding
  • History of bleeding tendency
  • History of asthma
  • Clinical diagnosis of chickenpox or influenza
  • History or presence of severe liver or kidney disease
  • Intake of short-acting analgesics (e.g. ASA, paracetamol, ibuprofen, diclofenac) either as a single ingredient or as part of a combination cold product in the last 6 hours, or intake of long-acting analgesics (e.g. naproxen) in the last 12 hours, or intake of any other NSAID in the last 24 hours
  • Use of any local or systemic short-acting cough and cold preparation (e.g. decongestant or antihistaminic drug) in the last 12 hours
  • Use of any cough or sore throat lozenges/candies or any menthol-containing product (including mentholated tissues) in the last 6 hours
  • Current intake or requirement of any prescription medication for the current treatment of acute respiratory tract illness
  • Administration of anticoagulants in the last 7 days
  • Inability to breathe through the nose or a history of chronic mouth breathing
  • Presence of any severe concomitant disease or condition which, in the opinion of the investigator, is a reason for exclusion, e.g. serious cardiovascular diseases (in particular arrhythmias), treatment with antiarrhythmics or methotrexate
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,088 participants (actual)

Study arms

  • Experimental
    Arm 1

    Drug: Acetylsalicylic acid (Aspirin, BAYE4465) & Lidocain

  • Active comparator
    Arm 2

    Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)

  • Active comparator
    Arm 3

    Drug: Lidocain

  • Placebo comparator
    Arm 4

    Drug: Placebo

Interventions

  • DrugAcetylsalicylic acid (Aspirin, BAYE4465) & Lidocain

    Single oral application of a fixed combination of Aspirin and Lidocain (as one lozenge)

  • Single oral application of Aspirin (as lozenge)

  • Single oral application of Lidocain (as lozenge)

  • DrugPlacebo

    Single oral application of Placebo (as lozenge)

06

What researchers measure

Primary outcomes

  1. Sum of pain intensity differences SPID

    Time frame: 120 minutes

  2. Pain intensity difference to baseline (PID12 min)

    Time frame: 12 minutes

  3. Pain intensity difference to baseline (PID120 min)

    Time frame: 120 minutes

Secondary outcomes

  1. Pain intensity difference to baseline (PID)

    Time frame: 3, 6, 12, 18, 24, 30, 40, 50, 60, 75, 90, 105, 120, 150, 180, 210 and 240 minutes post dose

  2. Total pain relief to baseline (TOTPAR)

    Time frame: 3, 6, 12, 18, 24, 30, 40, 50, 60, 75, 90, 105, 120, 150, 180, 210 and 240 minutes post dose

  3. Symptoms of common cold (headache, sinus pressure/pain, feverish discomfort, muscle aches and pain)

    Time frame: 60, 120, 180, and 240 minutes post dose

  4. Overall assessment of treatment

    Time frame: 240 minutes

  5. Assessment of safety and tolerability

    Time frame: 240 minutes

07

Study locations

19 sites
  • Mocow, 117574, Russian Federation
  • Moscow, 105064, Russian Federation
  • Moscow, 114765, Russian Federation
  • Moscow, 117321, Russian Federation
  • Moscow, 117342, Russian Federation
  • Moscow, 117393, Russian Federation
  • Moscow, 117418, Russian Federation
  • Moscow, 117421, Russian Federation
  • Moscow, 117485, Russian Federation
  • Moscow, 117513, Russian Federation
  • Moscow, 117588, Russian Federation
  • Moscow, 127299, Russian Federation
  • Novosibirsk, 630099, Russian Federation
  • Kiev, 02091, Ukraine
  • Kiev, 02222, Ukraine
  • Kiev, 02232, Ukraine
  • Kiev, 03049, Ukraine
  • Lugansk, 91011, Ukraine
  • Lugansk, 91055, Ukraine
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2004 to primary completion in May 2005, 5 months.

Of 17 phase 3 interventional studies under Common Cold, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2011
First posted
May 26, 2011
StartActual
Nov 30, 2004
Primary completionActual
May 28, 2005
CompletionActual
May 28, 2005
Last update
Oct 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01361399
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
May 26, 2011
Start date
Nov 30, 2004
Primary completion
May 28, 2005
Completion
May 28, 2005
Last update
Oct 18, 2023

Study contacts

Bayer Study Director
study director · Bayer
Bayer Study Director
Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aspirin

Start the discussion